FILE - This Thursday, Feb. 22, 2007, file photo shows the headquarters of biopharmaceutical company Actelion, in Allschwil, Switzerland. In a deal announced Thursday, Jan. 26, 2017, Johnson & Johnson is buying Swiss pharmaceutical Actelion in a $30 billion deal that will boost its treatments for life-threatening high blood pressure conditions. (Georgios Kefalas/Keystone via AP, File)
Featured Photo Galleries
